Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial

The Lancet Child & Adolescent Health · Elsevier

Аннотация

Publication date: December 2026 Source: The Lancet Child & Adolescent Health, Volume 10, Issue 12 Author(s): Carolyn Bolton Moore, Kristin Baltrusaitis, Edmund V Capparelli, Elizabeth D Lowenthal, Dwight E Yin, John H Moye, Christiana Smith, Michael Whitton, Conn M Harrington, Herta Crauwels, Rodica Van Solingen-Ristea, Mark A Marzinke, Barbara Heckman, Andi Ace, Shawn Ward, Kyle Whitson, Jenny Huang, S Y Amy Cheung, Brookie M Best, Ellen Townley

Читать у издателя →

Похожие статьи